<DOC>
	<DOCNO>NCT02913183</DOCNO>
	<brief_summary>Stroke one main severe disease public health importance . Recent study show old age one important factor influence outcome patient acute stroke , young plasma reverse age-related brain impairment mouse . Therefore , pilot study aim investigate whether young plasma effective alleviate brain injury neurologic deficit induce acute stroke patient .</brief_summary>
	<brief_title>Efficacy Safety Young Health Plasma Acute Stroke</brief_title>
	<detailed_description>This study enroll 78 stroke patient diagnose stroke meet inclusion criterion . After successfully meet initial screening criterion , investigator contact family , explain study , send consent form review . After , patient give 2 unit/day young health plasma ( young plasma exchange ) course 3 consecutive day , investigator make neurofunctional assessment 7 day , 30 day 90 day young health plasma treatment . And Magnetic Resonance brain , 7 day , 14 day 90 day young health plasma treatment .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<criteria>Age 6580 year Clinical presentation spontaneous intracerebral hemorrhage/ischemic stroke CT/MRI/MRA scan compatible spontaneous intracerebral hemorrhage/ ischemic stroke Time young plasma treatment &lt; 72 h symptom onset Glasgow Coma Score &gt; 6 initial presentation improvement Glasgow Coma Score &gt; 6 within time frame enrollment The firstever primary supratentorial intracerebral basal ganglia hemorrhage 530ml Signed date informed consent obtain TOAST : Largeartery atherosclerosis Patients undergo surgical evacuation intracerebral hemorrhage/ischemic stroke Inability undergo neuroimaging Magnetic Resonance Glasgow Coma Score &lt; 6 Significant past history disability , modify Rankin Scale（mRS）≥1 Primary intraventricular hemorrhage ICH due coagulopathy ( PT &gt; 15 International Normalized Ratio &gt; 1.3 , Partial Thromboplastin Time &gt; 36 ) trauma Thrombocytopenia : platelet count &lt; 100 000 Clinically significant hepatic disease demonstrate history , clinical exam ( ascites , varix ) , laboratory finding ( LFTs &gt; 2x normal , coagulopathy describe ) Comorbid condition likely complicate therapy include limited following : history New York Heart Association class II , III , IV Congestive Heart Failure ; endstage acquire immune deficiency syndrome Known pregnancy , positive pregnancy test , breast feeding Malignancy ( history active ) Bradyarrhythmia Atrioventricular Block Concomitant use antineoplastic , immunosuppressive immune modulate therapy Macular Edema Life expectancy le 90 day due comorbid condition Occurrences secondary intracerebral hemorrhage/ischemic stroke Patients know suspected able comply study protocol due alcoholism , drug dependency , noncompliance , live another state cause</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>acute stroke</keyword>
	<keyword>young health plasma</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
</DOC>